Hematopoietic Cell Transplantation for Miscellaneous Solid Tumors in Adults

This policy covers hematopoietic cell transplantation (autologous and allogeneic from bone marrow, peripheral blood, or umbilical cord blood), including HLA typing and conventional myeloablative conditioning, for selected adult solid tumors (e.g., prostate, rectal, renal cell, soft tissue sarcomas, stomach, thyroid, thymic, uterine, tumors of unknown primary) and for restoration of marrow/immune function after bone marrow–toxic cytotoxic therapy. Major limitations require medically fit patients for intense myeloablative regimens, mandate appropriate pretransplant conditioning and GVHD/infection management, and specify that HCT is considered experimental or unproven for many other solid tumors (e.g., lung, pancreatic, malignant melanoma, colon, esophageal, biliary and several gynecologic cancers) and that RIC/allogeneic approaches for metastatic solid tumors remain investigational.

"Hematopoietic cell transplantation (HCT) for prostate cancer"